
Absci Corp — Investor Relations & Filings
Absci Corp. is a generative AI drug creation company focused on developing biologic medicines. The company's Integrated Drug Creation Platform combines artificial intelligence with scalable wet lab technologies to design and validate novel therapeutics. This platform operates through iterative cycles of data generation, AI model training, de novo design of biologics like antibodies, and experimental validation. Absci's capabilities also include AI-enabled target discovery using a proprietary 'Reverse Immunology' approach. As a clinical-stage company, it advances an internal pipeline and collaborates with pharmaceutical partners to accelerate the development of differentiated biologics for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | |
| SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 35398073 | ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | ||
| 33052408 | SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33048944 | SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33035253 | S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 33035179 | 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 32896336 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896337 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896338 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-25 | English | ||
| 32896339 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 32896340 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 31233301 | 4 Filing | 2026-02-04 | English | ||
| 31233143 | 4 Filing | 2026-02-04 | English | ||
| 31233276 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31233114 | 4 Filing | 2026-01-30 | English | ||
| 12952145 | 8-K | 2026-01-14 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
PYC THERAPEUTICS LIMITED
Clinical-stage developer of RNA-based precision medicines f…
|
PYC | AU | Professional, scientific and te… |
|
Q32 Bio Inc.
A clinical-stage biotech developing therapies for autoimmun…
|
QTTB | US | Professional, scientific and te… |
|
QinetiQ Group PLC
A science and engineering company providing technology for …
|
GB | Professional, scientific and te… | |
|
Qualigen Therapeutics, Inc.
Clinical-stage biotech developing novel cancer treatments f…
|
QLGN | US | Professional, scientific and te… |
|
Quanterix Corp
Digitizes biomarker analysis with an ultra-sensitive digita…
|
QTRX | US | Professional, scientific and te… |
|
Quantum Base Holdings PLC
Develops quantum-secure fingerprints for product authentica…
|
QUBE | GB | Professional, scientific and te… |
|
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC
An R&D company using AI and quantum computing to enhance Bi…
|
QBT | GB | Professional, scientific and te… |
|
Quantumzyme Corp.
A biotransformation company specializing in enzyme engineer…
|
QTZM | US | Professional, scientific and te… |
|
QUIA PHARMA AB
Develops medicines using a proprietary drug delivery platfo…
|
QUIA | SE | Professional, scientific and te… |
|
Qurient Co., Ltd.
Clinical-stage biopharma developing drugs for oncology, cGv…
|
115180 | KR | Professional, scientific and te… |
Absci Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32931/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32931 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32931 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32931 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32931}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Absci Corp (id: 32931)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.